Journalists Put Polio, Price Transparency, and a Personal Covid Battle in Perspective
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
Cognitive Rehab May Help Older Adults Clear Covid-Related Brain Fog
People whose brains have been injured by concussions, traumatic accidents, strokes, or neurodegenerative conditions such as Parkinson’s disease can benefit from targeted therapy. Experts also employ therapies for long-covid patients with memory and language problems.
KHN’s ‘What the Health?’: Kansas Makes a Statement
In the first official test vote since the Supreme Court overturned Roe v. Wade, voters in Kansas’ primary said in no uncertain terms they want to keep a right to abortion in their state constitution. Meanwhile, the Senate is still working to reach a vote before summer recess on its health care-climate-tax measure, but progress is slow. Tami Luhby of CNN, Sandhya Raman of CQ Roll Call, and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KHN’s Bram Sable-Smith, who wrote the latest KHN-NPR “Bill of the Month” installment about a very expensive ambulance trip.
The Time Has Come for DIY Mandates on Covid
Yes, lots of us suffer from pandemic fatigue and have been getting sloppy about precautions in recent months. But with covid an ongoing menace — and governments reluctant to return to sweeping mandates — it’s time for all of us to step up our game.
KHN’s ‘What the Health?’: Manchin Makes a Deal
In a rare surprise for official Washington, Senate Majority Leader Chuck Schumer and Sen. Joe Manchin (D-W.Va.) announced a deal to expand the planned health bill in the Senate to include provisions raising taxes and addressing climate change. The measure would include a third year of expanded subsidies for the Affordable Care Act, but not health care coverage for people left out of Medicaid in states that failed to expand the program. Meanwhile, the ACA goes back to court, and the Biden administration restores anti-discrimination protections for LGBTQ+ people that were rolled back by the Trump administration. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Sarah Karlin-Smith of the Pink Sheet, and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Dr. Céline Gounder of KHN about the latest on the monkeypox outbreak.
Lo que debes saber sobre Paxlovid para tratar covid, en especial, ¿debes tomarlo?
Desde que Paxlovid comenzó a estar disponible hace siete meses, ha eclipsado otras terapias disponibles para prevenir los síntomas graves de covid en pacientes de alto riesgo. Algunos médicos se apresuran a recetarlo, pero como ocurre con tanto sobre la pandemia de covid, hay controversia.
Everything You Need to Know About Paxlovid — Especially, Should You Take It?
Paxlovid has eclipsed other available therapies for preventing life-threatening covid symptoms in high-risk patients. But even as doctors praise its effectiveness, many say they have unanswered questions about prescribing the drug and want more and better data about it.
KHN’s ‘What the Health?’: Drug Price Bill Is a Go in the Senate
Two things happened in Washington this week that were inevitable: President Joe Biden tested positive for covid-19, and the Senate agreed to move forward on a budget bill that includes only a sliver of what Biden hoped it would. Still, the bill to allow Medicare to negotiate some drug prices, cap out-of-pocket drug costs for seniors, and extend temporary subsidies for Affordable Care Act insurance premiums would represent a major step if Democrats can get it across the finish line. Meanwhile, abortion battles continue to escalate around the country, with Texas leading the way in restrictions. Shefali Luthra of The 19th, Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Dr. Jack Resneck Jr., the new president of the American Medical Association.
¿Ponerse el refuerzo ahora o esperar? Muchos se preguntan cómo navegar la próxima ola de covid
Aproximadamente el 70% de los estadounidenses de 50 años o más que recibieron una primera vacuna de refuerzo contra covid, y casi la misma cantidad de personas de 65 años o más, no han recibido un segundo, según datos de los CDC.
Boost Now or Wait? Many Wonder How Best to Ride Out Covid’s Next Wave
As the country faces a rise in new infections driven by the omicron BA.5 subvariant of the coronavirus, about 70% of people 50 and older who got a first covid-19 booster shot haven’t received the recommended second one, according to the Centers for Disease Control and Prevention. Many undervaccinated Americans have lost interest, and others aren’t sure whether to get boosted again now or wait for vaccines reformulated to target newer strains of the virus.
A Free-for-All From Readers and Tweeters, From Medical Debt to Homelessness
KHN gives readers a chance to comment on a recent batch of stories.
‘An Arm and a Leg’: One ER Doctor Grapples With the Inequities of American Health Care
This episode is an interview with Dr. Thomas Fisher, author of “The Emergency: A Year of Healing and Heartbreak in a Chicago ER.”
Feds Want a Policy That Advocates Say Would Let Hospitals Off the Hook for Covid-Era Lapses
The pandemic disrupted all sense of normalcy for U.S. hospitals, so federal officials are proposing to pause financial penalties against the facilities and to block public access to key hospital safety data — such as the frequency of falls and sepsis — because of concerns that the data isn’t accurate enough. But consumer advocates are furious about the proposal.
‘My Body, My Choice’: How Vaccine Foes Co-Opted the Abortion Rallying Cry
Anti-vaccine advocates discovered a catchy, succinct, and potent slogan. Its unlikely source: the abortion rights movement.
Cómo Pfizer le ganó a la pandemia, alcanzando influencia y ganancias descomunales
Su éxito en el desarrollo de medicamentos contra covid le ha dado a la farmacéutica un peso inusual en la determinación de la política de salud de Estados Unidos. Algo que preocupa a expertos.
How Pfizer Won the Pandemic, Reaping Outsize Profit and Influence
The drugmaker has the best-selling vaccine to prevent covid and the most effective drug to treat it. Its success has overshadowed the government’s covid-fighting strategy.
KHN’s ‘What the Health?’: A World Without ‘Roe’
The Supreme Court’s decision overturning Roe v. Wade has created far more questions than it has answered about the continued legality and availability of abortion, as both abortion rights supporters and anti-abortion activists scramble to put their marks on policy. Meanwhile, Congress completes work on its gun bill and the FDA takes up the problem of the next covid-19 booster. Margot Sanger-Katz of The New York Times, Sarah Karlin-Smith of the Pink Sheet, and Victoria Knight of KHN join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KHN’s Angela Hart, who reported and wrote the latest KHN-NPR “Bill of the Month” episode about two identical eye surgeries with very different price tags.
Readers and Tweeters Weigh In on Medical Debt, the Obesity Epidemic, and Opioid Battles
KHN gives readers a chance to comment on a recent batch of stories.
KHN’s ‘What the Health?’: Closing In on Covid Vaccines for ‘The Littles’
The wait is nearly over for parents of kids under 5 as a key advisory committee to the FDA recommends authorizing a covid-19 vaccine for the youngest children. Meanwhile, Congress is struggling to fill in the details of its gun control compromise, and, as the Supreme Court prepares to throw the question of abortion legality back to the states, the number of abortions has been rising. Shefali Luthra of The 19th, Sarah Karlin-Smith of the Pink Sheet, and Sandhya Raman of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
At a Bay Area ‘Test-to-Treat’ Site, Few Takers for Free Antivirals
In carrying out the federal covid-19 “test-to-treat” initiative, California is targeting the uninsured by outfitting 138 testing sites with screenings for free antiviral drugs. But as of mid-June, fewer than 800 people had been prescribed the medicines. And two-thirds of those undergoing screenings are insured.